ENETS Abstract Search

Somatostatin Analogs in Patients with Zollinger Ellison Syndrome (ZES): An Observational Study


Introduction: Zollinger Ellison syndrome (ZES) is a rare syndrome caused by gastrin hypersecretion from a primary neuroendocrine tumor (NET), usually located within the duodenum or into the pancreas. Gastrinomas have two important treatment goal: the control of the gastrin-excess state and the control of tumor growth.

Aim(s): While therapy for the syndrome control is univocal and based on proton pump inhibitors (PPI), the one for disease control is the most debated only few and small studies explored the role of somatostatin analogs (SSAs) therapy in ZES.

Materials and methods: A retrospective study on 33 patients with ZES (18 F, median age 48 yrs), followed and managed from 1990 to 2019

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: massironi s

Authors: Massironi S, Peracchi M, Elvevi A, Cristoferi L, Quatrini M,

Keywords: ZES, gastrinoma, somatostatin analogs,

To read the full abstract, please log into your ENETS Member account.